Related references
Note: Only part of the references are listed.Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis
Lucy Platt et al.
ADDICTION (2018)
Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review
Sarah Larney et al.
LANCET GLOBAL HEALTH (2017)
Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation
Natasha K. Martin et al.
JOURNAL OF HEPATOLOGY (2016)
Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013
Louisa Degenhardt et al.
LANCET INFECTIOUS DISEASES (2016)
Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold
Karl Claxton et al.
HEALTH TECHNOLOGY ASSESSMENT (2015)
HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact
N. K. Martin et al.
JOURNAL OF VIRAL HEPATITIS (2015)
Community health workers: A bridge to healthcare for people who inject drugs
Kirsty Morgan et al.
INTERNATIONAL JOURNAL OF DRUG POLICY (2015)
Extremely low and sustained HIV incidence among people who inject drugs in a setting of harm reduction
Jenny Iversen et al.
AIDS (2014)
Financing structural interventions: going beyond HIV-only value for money assessments
Michelle Remme et al.
AIDS (2014)
Eradication of Hepatitis C Infection: The Importance of Targeting People Who Inject Drugs
Margaret Hellard et al.
HEPATOLOGY (2014)
Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis
Esther J. Aspinall et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2014)
Rapid Decline in HCV Incidence among People Who Inject Drugs Associated with National Scale-Up in Coverage of a Combination of Harm Reduction Interventions
Norah E. Palmateer et al.
PLOS ONE (2014)
Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma A Meta-analysis of Observational Studies
Rebecca L. Morgan et al.
ANNALS OF INTERNAL MEDICINE (2013)
Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence
Khayriyyah Mohd Hanafiah et al.
HEPATOLOGY (2013)
Housing Instability among People Who Inject Drugs: Results from the Australian Needle and Syringe Program Survey
Libby Topp et al.
JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE (2013)
Prevalence of, and risk factors for, HIV, hepatitis B and C infections among men who inject image and performance enhancing drugs: a cross-sectional study
Vivian D. Hope et al.
BMJ OPEN (2013)
Injecting drug users in Scotland, 2006: Listing, number, demography, and opiate-related death-rates
Ruth King et al.
ADDICTION RESEARCH & THEORY (2013)
Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings
Peter Vickerman et al.
ADDICTION (2012)
Estimating the cost-effectiveness of needle-syringe programs in Australia
Jisoo A. Kwon et al.
AIDS (2012)
Respondent driven sampling and community structure in a population of injecting drug users, Bristol, UK
H. L. Mills et al.
DRUG AND ALCOHOL DEPENDENCE (2012)
Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis
Adriaan J. van der Meer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
The cost-effectiveness of public health interventions
Lesley Owen et al.
JOURNAL OF PUBLIC HEALTH (2012)
The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence
Katy M. E. Turner et al.
ADDICTION (2011)
The cost-effectiveness of consistent and early intervention of harm reduction for injecting drug users in Bangladesh
Lorna Guinness et al.
ADDICTION (2010)
Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews
Norah Palmateer et al.
ADDICTION (2010)
Predicting Mortality Risk in Patients With Compensated HCV-Induced Cirrhosis: A Long-Term Prospective Study
Savino Bruno et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Injecting-related injury and disease among clients of a supervised injecting facility
Allison M. Salmon et al.
DRUG AND ALCOHOL DEPENDENCE (2009)
Frequency, factors and costs associated with injection site infections: Findings from a national multi-site survey of injecting drug users in England
Vivian Hope et al.
BMC INFECTIOUS DISEASES (2008)
The cost-effectiveness of expanding harm reduction activities for injecting drug users in Odessa, Ukraine
Peter Vickerman et al.
SEXUALLY TRANSMITTED DISEASES (2006)
The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide
Joseph F. Perz et al.
JOURNAL OF HEPATOLOGY (2006)
Do needle syringe programs reduce HIV infection among injecting drug users: A comprehensive review of the international evidence
Alex Wodak et al.
SUBSTANCE USE & MISUSE (2006)
The cost-effectiveness of HIV preventive measures among injecting drug users in Svetlogorsk, Belarus
L Kumaranayake et al.
ADDICTION (2004)
Share Paper
